PatientLikeMe-FDA collaboration to study patient generated healthcare data

patient generated healthcare data

PatientsLikeMe-FDA collaboration to study patient generated healthcare data

The FDA and PatientsLikeMe have consented to join hands for a research to diagnose how patient-reported data can help discern or revamp drug safety.

Recent growth in buyer-directed computing technology has prompted bio-medically-significant information streams with potential health implementations. This has kindled universal fascination for Patient Generated Health Data (PGHD), characterized as well being related information – including symptoms, physical history, lifestyle decisions, biometric information, and treatment history, among other data made, recorded, accumulated, or construed by or from patients or their designees (individuals who help them) to help address a health issue.

The FDA, that is responsible for ensuring the general wellbeing by guaranteeing the protection, accuracy, and security of human and veterinary medications, antibodies and other biological items for use by humans, and medical gadgets have consented to a join hands with PatientsLikeMe for researching to efficiently investigate the ability of patient-generated information to illuminate administration on activities identified with risk management and risk evaluation.

PatientsLikeMe is the biggest and most dynamic patient network on the web, with over three hundred thousand individuals giving an account of their true experiences with more than twenty-four hundred conditions. The alliance was announced at the Drug Information Association’s (DIA) yearly gathering in Washington D.C.

PGHD is different from information created in clinical settings and through experiences as here, it is the patients and not suppliers, who are fundamentally in charge of recording this information and also it is the patients that choose how to share or issue this information to health insurance suppliers and others.

For an example, a patient checking his pulse or blood glucose with home health gear, or tracking his exercise and eating routine utilizing a web application or device worn on the body.

President and Co-Founder of PatientsLikeMe, Ben Heywood, said that this understanding is a phenomenal advancement towards informing regulatory science and strengthening post-market surveillance. He said that most clinical evaluations just speak for the experience of at most a few thousand patients, making it difficult to foresee all the potential bad symptoms of medications in reality. Patient-generated information gives a more unabridged/bigger picture of a medication’s safety by giving a window into patients’ lives and experiences from health care encounters, over a period of time.

The organization’s initiatives for drug safety started in 2008 with the launch of a trial program that permitted patients living with Multiple Sclerosis (MS) to account for unfavourable occasions straight to the FDA. After one year the organization introduced the primary drug safety platform via social networking media, empowering industry associates to meet their regulatory commitments.

Talking about PatientsLikeMe, they have gathered more than 115,000 unfavourable accounts of 1,000 nonidentical medications, information that the FDA can now examine and scrutinize as a supplement to using traditional references, like FAERS.

Although PatientsLikeMe has either worked with or counselled government groups like the National Institute of Health, the Institute of Medicine, the U.S. Division of Health and Human Services, and also not-for-profit corporations like the PCORI, it is a first for PatientsLikeMe informally working with the FDA.

They undertook a Research Collaboration Agreement in April of 2015. Around the same time, even the ONC recognized the application of PGHD as a key issue for furthering research and patient participation and started with the task of discovering the best practices, voids, and openings for improvement in usage and collection of PGHD in research and care delivery through 2024.

It will be vital to observe after how these coordinated efforts play out, and how FDA makes use of a newly acquired extensive variety of conceivably complex patient information. Or if they will face challenges like they did in the development of medical devices for opioids.

Image credit: www.istockphoto.com

0 Comments

Leave a reply

Your email address will not be published. Required fields are marked *

*

© 2018 Dr. Hempel Digital Health Network

 
or

Log in with your credentials

Forgot your details?